The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage ...

People living with chronic obstructive pulmonary disease (COPD) typically rely on maintenance inhalers to manage their daily symptoms. They may also take rescue inhalers for sudden breathing ...

Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...

In May 2025, the FDA approved mepolizumab (Nucala) as a treatment for chronic obstructive pulmonary disease (COPD). Before any drug gets near a pharmacy shelf, it starts with years of basic science ...

FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...

COPD is a group of progressive lung diseases that includes emphysema and chronic bronchitis. Despite affecting an estimated 32 million people in the United States, as many as half are unaware they ...

Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved ...

“COPD is an urgent global health concern and a notoriously difficult-to-treat disease due to its heterogeneity, with no novel treatments approved in more than a decade,” said George D. Yancopoulos, ...

New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...